Anti-TNF agent etanercept augments UV-induced skin cancer development in SKH-1 mice

References

• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072.
   PubMed Web of Science ®Google Scholar
• Blaha P, Bigenzahn S, Koporc Z, et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood. 2003;101(7):2886–2893.
   PubMed Web of Science ®Google Scholar
• Fries W, Muja C, Crisafulli C, et al. Infliximab and etanercept are equally effective in reducing enterocyte APOPTOSIS in experimental colitis. Int J Med Sci. 2008;5(4):169–180.
   PubMedGoogle Scholar
• Werner RN, Stockfleth E, Connolly SM, et al. Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis – International League of Dermatological Societies in cooperation with the European Dermatology Forum – Short version. J Eur Acad Dermatol Venereol. 2015;29(11):2069–2079.
   PubMed Web of Science ®Google Scholar
• Bottomley MJ, Thomson J, Harwood C, et al. The role of the immune system in cutaneous squamous cell carcinoma. IJMS. 2019;20(8):2009.
   Google Scholar
• Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet. 2001;358(9287):1042–1045.
   PubMed Web of Science ®Google Scholar
• Belinchon I, Arribas MP, Soro P, et al. Recovery of the response to biological treatments using narrow band ultraviolet-B in patients with moderate to severe psoriasis: a retrospective study of 17 patients. Photodermatol Photoimmunol Photomed. 2014;30(6):316–322.
   PubMed Web of Science ®Google Scholar
• Foley PA, Quirk C, Sullivan JR, et al. Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence. J Eur Acad Dermatol Venereol. 2010;24(10):1135–1143.
   PubMed Web of Science ®Google Scholar
• Gambichler T, Tigges C, Scola N, et al. Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks. Br J Dermatol. 2011;164(6):1383–1386.
   PubMed Web of Science ®Google Scholar
• Kircik L, Unite Study Group, Bagel J, Korman N, Menter A, Elmets CA, Koo J, et al. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol. 2008;7(3):245–253.
   PubMed Web of Science ®Google Scholar
• Wolf P, Hofer A, Weger W, et al. 311 nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients. Photodermatol Photoimmunol Photomed. 2011;27(4):186–189.
   PubMed Web of Science ®Google Scholar
• Wolf P, Weger W, Legat FJ, et al. Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial. Br J Dermatol. 2012;166(1):147–153.
   PubMed Web of Science ®Google Scholar
• Seror R, Mariette X. Malignancy and the risks of biologic therapies: current status. Rheum Dis Clin North Am. 2017;43(1):43–64.
   PubMed Web of Science ®Google Scholar
• Beyaert R, Beaugerie L, Van Assche G, et al. Cancer risk in immune-mediated inflammatory diseases (IMID). Mol Cancer. 2013;12(1):98.
   PubMed Web of Science ®Google Scholar
• van Lumig PP, Menting SP, van den Reek JM, et al. An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors. J Eur Acad Dermatol Venereol. 2015;29(4):752–760.
   PubMed Web of Science ®Google Scholar
• Naldi L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies. Clin Dermatol. 2010;28(1):88–92.
   PubMed Web of Science ®Google Scholar
• Pierard-Franchimont C, Pierard GE, Quatresooz P. Focus on skin cancer association and progression under TNF antagonist therapy. Expert Opin Biol Ther. 2011;11(9):1215–1222.
   PubMed Web of Science ®Google Scholar
• Kock A, Schwarz T, Kirnbauer R, et al. Human keratinocytes are a source for tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light. J Exp Med. 1990;172(6):1609–1614.
   PubMed Web of Science ®Google Scholar
• Skov L, Hansen H, Allen M, et al. Contrasting effects of ultraviolet A1 and ultraviolet B exposure on the induction of tumour necrosis factor-alpha in human skin. Br J Dermatol. 1998;138(2):216–220.
   PubMed Web of Science ®Google Scholar
• Li B, Vincent A, Cates J, et al. Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Res. 2009;69(1):338–348.
   PubMed Web of Science ®Google Scholar
• Faurschou A. Role of tumor necrosis factor-α in the regulation of keratinocyte cell cycle and DNA repair after ultraviolet-B radiation. Dan Med Bull. 2010;57(10):B4179.
   PubMedGoogle Scholar
• Mitoma H, Horiuchi T, Hatta N, et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology. 2005;128(2):376–392.
   PubMed Web of Science ®Google Scholar
• Leloup P, Daviet V, Chiffoleau A, et al. Urticaria pigmentosa after treatment with TNF antagonists: a case report. Arch Dermatol. 2011;147(12):1459–1460.
   PubMedGoogle Scholar
• Valejo Coelho MM, Matos TR, Apetato M. The dark side of the light: mechanisms of photocarcinogenesis. Clin Dermatol. 2016;34(5):563–570.
   PubMed Web of Science ®Google Scholar